Nonadherence to paroxetine: A study based on monitoring plasma paroxetine levels

Journal of Clinical Psychopharmacology

Volumn 30, Issue 1, 2010, Pages 82-83

  Yoshimura, Reiji ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Hori, Hikaru ^a   Ueda, Nobuhisa ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

DEPRESSION; DRUG BLOOD LEVEL; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; SELF REPORT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; DRUG MONITORING; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 74549153257     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181ca7f51     Document Type: Letter

References (9)

1. Rausch JL, Hobby HM, Shendarkar N, et al. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis. J Clin Psychopharmacol. 2001;21:139-142.
2. Akerblad AC, Benqtsson FF, Von Knorring L, et al. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol. 2006;21:117-124.
3. Brook OH, Van Hout HP, Staleman WA, et al. Nontricyclic antidepressants: predictors of nonadherence. J Clin Psychopharmacol. 2006;26:643-647.
4. Fujita A, Azuma H, Kitamura T, et al. Adequacy of continuation and maintenance treatments for major depression in Japan. J Psychopharmacol. 2008;22:153-156.
5. Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44:300-303.
6. Bies RR, Gastonquary MR, Coley KC, et al. Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. Am J Geriatr Pharmacother. 2002;10:696-705.
7. Bies RR, Mulsant BH, Rosen J, et al. Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. Am J Geriatr Pharmacother. 2005;3:87-91.
8. Miyamoto K, Yoshimura R, Ueda N, et al. Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients. Hum Psychopharmacol. 2007;22:483-490.
9. Feng Y, Pollock BG, Ferrell RE, et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol. 2006;61:558-569.